Loading clinical trials...
Loading clinical trials...
An Adaptive PET Study in Healthy Volunteers Using [11C]GSK931145 to Establish the Relationship of Glycine Transporter 1 Occupancy by GSK1018921 to Plasma Concentrations Over Time.
A PET study using \[11c\]GSK931145 to characterise the exposure-occupancy relationship over time for GSK1018921.
This is an open-label, adaptive-design, single-dose, non randomized PET occupancy study.The primary aim of this study is to describe the relationship between plasma concentrations and brain occupancy of GSK1018921 over time. Up to 22 healthy volunteers will be administered single doses of GSK1018921 in order to obtain 12 evaluable complete data sets of occupancy estimates.
Age
18 - 55 years
Sex
MALE
Healthy Volunteers
Yes
GSK Investigational Site
Barcelona, Spain
Start Date
May 19, 2008
Primary Completion Date
December 22, 2008
Completion Date
December 22, 2008
Last Updated
July 18, 2017
12
ACTUAL participants
GSK1018921
DRUG
Lead Sponsor
GlaxoSmithKline
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions